platoseedplatoseed
Gilgamesh Pharmaceuticals, a Clinical stage biotechnology company…
Gilgamesh is a pioneering, clinical stage mental health science-focused biotechnology company. We have a disciplined focus on developing innovative new chemical entities (NCEs) leveraging a unique combination of medicinal chemistry, intellectual property strategy, neuroscience & neurobiology, and drug development expertise. We are an experienced team, with proven success in biotech exits and inventions.
Gilgamesh Pharma is a clinical-stage biotechnology company focused on developing precision therapies for psychiatric diseases, leveraging a multimodal discovery platform to accelerate novel chemical entities and translational science. Their programs aim for rapid-acting, durable treatments that target brain plasticity rather to mere symptom management. The company has a collaboration with AbbVie and has achieved notable progress including assets acquired and Phase 2a results.
The company discovers and develops novel chemical entities (NCEs) for psychiatric conditions using a multimodal platform that combines medicinal chemistry, neurocircuitry-focused translational science, and machine learning. Their pipeline includes five programs with specific assets: Bretisilocin (GM-2505) – a rapid-acting 5-HT2A receptor agonist acquired by AbbVie; Blixeprodil (GM-1020) – an orally bioavailable NMDAR antagonist with rapid antidepressant effects; Neuroplastogens – non-hallucinogenic neuroplastogens developed in partnership with AbbVie; GM-3009 – safer ibogaine analogs addressing OUD/PTSD/TBI with improved cardiac safety; M1/M4 Agonist – muscarinic receptor agonist targeting schizophrenia with refined selectivity and reduced peripheral side effects. The platform emphasizes accelerated NCE identification, detailed SAR data, and translational advancement from concept to clinic, supported by clinical execution teams and leadership with CNS drug development experience.
Who it’s for: Psychiatric disorders including major depressive disorder, anxiety, addiction (OUD), PTSD, traumatic brain injury, and schizophrenia; pharmaceutical companies and research organizations seeking next-generation CNS therapies.
Financing and acquisitions (AbbVie asset acquisition), press announcements of Series A funding and Phase 2a results; notable recognition (Fierce 15) and acquisitions indicate traction.
Duke University BS, MD from University of Miami, former Chief of Psychiatry in Boston Area. Academic work at Mass General Hospital and NIH (intramural), researcher at JNJ in psychiatry and neurology, and then at Pfizer Inc in NYC (Clinical Disease Area Expert in Neuroscience Area), Founder of start up, Perception Neuroscience (exited) and was CSO, and now Founder of Gilgamesh. Live in NYC and mountains of NC. Assistant Professor of Psychiatry and Exp Therapeutics at Columbia University
I am a medicinal chemist, pharmacologist, and entrepreneur with extensive experience in the design and preclinical development of psychoactive drugs for the future treatment of psychiatric illnesses. In the context of my entrepreneurial endeavors I have also built significant expertise in business, fundraising, operations, and intellectual property strategy.
Professor of Chemistry at Columbia University with expertise in synthetic chemistry, medicinal chemistry, molecular design, synaptic imaging, neuropharmacology, and experimental therapeutics. Led new conceptual advances in chemical synthesis (C-H bond functionalization), developed fluorescent false neurotransmitters (FFNs), elucidated the mechanism of action of antidepressant tianeptine, expertise in iboga alkaloid and mitragynines chemistry and pharmacology.
AI platform accelerating therapies for rare & inflammatory diseases.
We create activating antibodies to treat diseases others can’t.
